Q
Q.B.I. Enterprises
Clinical-Stage Pharmaceutical Company
About Q.B.I. Enterprises
Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the discovery and development of novel RNA interference (RNAi) based therapeutics. The company focuses on creating treatments for conditions such as acute kidney injury and ocular diseases. Quark operates in the biopharmaceutical market, targeting both healthcare providers and patients in need of advanced therapeutic solutions. The business model revolves around the research and development of RNAi-based drugs, progressing through various clinical trial phases to ensure efficacy and safety. Revenue is primarily generated through partnerships, licensing agreements, and potential future sales of approved drugs. Quark's leading products include QPI-1002, currently in Phase III trials for the prevention of acute kidney injury following cardiac surgery, and QPI-1007, also in Phase III trials for ocular diseases. The company aims to leverage its proprietary RNAi technology to address unmet medical needs and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1994
- Headquarters
- Fremont, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 27.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Medical Research, Drug Development, Molecular Biology, Alternative Protein, Macro-Nutrients, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jun 2010 | $10M | $40M | Undisclosed | — |
| LATE VCOther financing | Jul 2008 | $27M | $108M | Undisclosed | — |
Growth signals
Latest recorded traffic for Q.B.I. Enterprises is 120 monthly website visits, up 20% over the last three months. Q.B.I. Enterprises's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
SBI Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Q.B.I. Enterprises on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Q.B.I. Enterprises’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.